Pharmacokinetics and safety of single oral doses of VX-366 (isobutyramide) in healthy volunteers

Journal of Clinical Pharmacology

Volumn 36, Issue 7, 1996, Pages 617-622

  Brettman, Lee R ^a   Chaturvedi, Pravin R ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; ISOBUTYRAMIDE; UNCLASSIFIED DRUG; VX 366;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; HEADACHE; HEMOGLOBIN SYNTHESIS; HEMOGLOBINOPATHY; HUMAN; HUMAN EXPERIMENT; MALE; MUSCLE WEAKNESS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT OUTCOME; VERTIGO; VOMITING;

EID: 0029766083     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04226.x     Document Type: Article

References (17)

1. Sher GD, Ginder GD, Little J, Yang S, Dover GJ, Olivieri NF: Extended therapy with intravenous arginine butyrate in patients with β-hemoglobinopathies. N Engl J Med 1995;332:1606-1610.
2. Goldberg MA, Husson MA, Bunn HF: Participation of hemoglobins A and F in polymerization of sickle hemoglobin. J Biol Chem 1977;252:3414-3421.
3. Voskaridou E, Kalotychou V, Loukopoulos D: Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell β-thalassemia. Br J Haematol 1995;89:479-484.
4. Noguchi CT, Rodgers GP, Serjeant G, Schechter AN: Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med 1988;318:96-99.
5. Adams JG, Coleman MB: Simian switching suggests solution to the symptoms of the sickle cell syndromes. Exp Hematol 1992;20: 1151-1153.
6. Hajjar FM, Pearson HA: Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr 1994;125:490-492.
7. Perrine SP, Greene MF, Faller DV: Delay in the fetal globin switch in infants of diabetic mothers. N Engl J Med 1985;312:334-338.
8. Perrine SP, Miller BA, Faller DV, Cohen RA, Vichinsky EP, Hurst D, et al: Sodium butyrate enhances fetal globin gene expression in erythroid progenitors of patients with Hb SS and E1 thalassemia. Blood 1989;74:454-459.
9. Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta T, Witkowska HE, et al: A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N Engl J Med 1993;328:81-86.
10. Daniel P, Brazier M, Cerutti I, Pieri F, Tardivel I, Desmet G, et al: Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts. Clin Chim Acta 1989;181:255-264.
11. Miller AA, Kurschel E, Osieka R, Schmidt CG: Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 1987;23:1283-1287.
12. Sher GD, Enispah B, Ginder G, Dover G, Little J, Donsky J, et al: Intravenous infusion of arginine butyrate increases g-globin mRNA Expression and F-reticulocytes in patients with homozygous β-thalassemia and sickle cell disease (abstract no. 1233). Blood 1993;82(suppl 1):312a.
13. Costin D, Dover G, Olivieri N, Beutler E, Walsh CT, Torkelson S: Clinical use of the butyrate derivative isobutyramide in the E1 globin disorders (abstract 1413). Blood 1993;82(suppl 1):357a.
14. Perrine SP, Dover GH, Daftari P, Walsh CT, Jin YX, Mays A, Faller DV: Isobutyramide, an orally bioavailable butyrate analogue, stimulates fetal globin gene expression in vitro and in vivo. Br J Haematol 1994;88:555-561.
15. Gibaldi M, Perrier D: Pharmacokinetics. Second edition. New York: Marcel Dekker, 1982.
16. Shepard TA, Lordi N, Sparrow PE: Influence of dose range on degree of nonlinearity detected in dose-proportionality studies for drugs with saturable elimination: single-dose and steady-state studies. Pharm Res 1993;10:289-293.
17. Perrine SP, Faller DV: Butyrate-induced reactivation of the fetal globin genes: a molecular treatment for β-hemoglobinopathies. Experientia 1993;49:133-137.